### ðŸ«  Cardiomyopathy: Atrial Fibrillation Management in Hypertrophic Cardiomyopathy

#### âœ… True Statements
1. **Atrial fibrillation** is common in patients with **hypertrophic cardiomyopathy (HCM)** and should be managed with **rate control** and **anticoagulation**, with early consideration of a **rhythm control strategy**.
2. During **atrial fibrillation with rapid ventricular response**, **shortened diastolic filling** can worsen **diastolic dysfunction** and exacerbate **left ventricular outflow tract (LVOT) gradient**, leading to worsened symptoms in patients with **HCM**.
3. Patients with **HCM** and **atrial fibrillation** should receive **anticoagulation therapy** to prevent **thromboembolic complications**, regardless of their **CHAâ‚‚DSâ‚‚-VASc score**.
4. The 2020 **American College of Cardiology/American Heart Association (ACC/AHA)** guidelines recommend **direct oral anticoagulants (DOACs)** such as **apixaban** or **rivaroxaban** as first-line therapy for **HCM with atrial fibrillation**, with **vitamin K antagonists** as a second-line option.
5. **Amiodarone** should not be started in a **stable patient** with **atrial fibrillation** and **HCM** who has not yet received **anticoagulant therapy**, due to the risk of **cardioversion-related thromboembolism**.
6. Patients with **HCM** and **atrial fibrillation** often remain **symptomatic despite rate control**, and rhythm control along with anticoagulation should be considered.
7. **Aspirin** is insufficient to prevent **thromboembolic complications** in patients with **HCM and atrial fibrillation** and should not be used as monotherapy.
8. If **rate control** is already achieved with **metoprolol**, additional **atrioventricular nodal blocking agents** such as **diltiazem** are not required.

#### ðŸ’¬ Extra
1. Rhythm control is often necessary because symptoms may persist even after rate control in HCM.
3. Elevated stroke risk in HCM persists even in the absence of traditional CHAâ‚‚DSâ‚‚-VASc risk factors.
5. Anticoagulation should precede any attempts at cardioversion to reduce embolic risk.
8. Metoprolol may be uptitrated for further rate control if needed.

#### ðŸ”· Tags
#Cardiology #EmergentCare #HypertrophicCardiomyopathy #AtrialFibrillation #Apixaban #StrokePrevention #CHA2DS2VASc #RateControl #RhythmControl

#### ðŸ“™ Reference
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2020;142:e558-e631. PMID: 33215931 doi:10.1161/CIR.0000000000000937

#### ðŸ†” Question ID
CVMCQ24070

#### ðŸ•’ Last Updated
January 2025

---

#### ðŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Hypertrophic Cardiomyopathy, Management of Hypertrophic Cardiomyopathy

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **Therapeutic lifestyle interventions** in patients with **hypertrophic cardiomyopathy (HCM)** and **overweight or obesity** can reduce the risk of **left ventricular outflow tract (LVOT) obstruction**, **heart failure**, and **atrial fibrillation**.
2. Patients with **hypertrophic cardiomyopathy** should avoid **dehydration**, **excess alcohol**, and **vasodilatory exposures** (e.g., **saunas**, **hot tubs**) to prevent **LVOT obstruction**.
3. **Mild- to moderate-intensity recreational exercise** is generally **safe and beneficial** for patients with **HCM**.
4. In **symptomatic patients** with **HCM**, **nonvasodilating Î²-blockers** such as **metoprolol** should be titrated to maximum tolerated doses.
5. **Vasodilating Î²-blockers** such as **carvedilol**, **labetalol**, and **nebivolol** should be **avoided** in patients with **HCM**.
6. **Disopyramide**, a class IA antiarrhythmic with **negative inotropic effects**, can be added for patients with **LVOT obstruction and persistent symptoms** despite Î²-blockers or **verapamil/diltiazem**.
7. **Digoxin** should be **avoided** in patients with **HCM and atrial fibrillation** because its **positive inotropic effects** may worsen **LVOT obstruction**.
8. All patients with **HCM and atrial fibrillation** should receive **anticoagulation**, regardless of **CHAâ‚‚DSâ‚‚-VASc score**.
9. **Direct oral anticoagulants (DOACs)** are considered **first-line** for **HCM with atrial fibrillation**; **warfarin** is second-line.
10. **Ambulatory electrocardiogram (ECG) monitoring** should be performed at diagnosis and every **1 to 2 years** in patients with **HCM**, or sooner with **symptoms** such as **palpitations or syncope**.
11. **Repeat transthoracic echocardiography (TTE)** is recommended with **new cardiac symptoms** or every **1 to 2 years** in **asymptomatic** patients with **HCM**.
12. The **cardiac myosin inhibitor mavacamten** is FDA approved for **symptomatic obstructive hypertrophic cardiomyopathy (HCM)** and works by **decreasing actin-myosin cross-bridge formation**, thereby **reducing hypercontractility**.
13. **Surgical septal myectomy** is favored over **alcohol septal ablation** in **younger patients with obstructive HCM** or those needing **concomitant cardiac surgery**, due to **higher rates of symptom resolution** and **lower recurrence**.
14. An **implantable cardioverter-defibrillator (ICD)** is recommended in patients with **hypertrophic cardiomyopathy (HCM)** and **systolic dysfunction** for **primary prevention of sudden cardiac death**.
15. An **electrocardiogram (ECG)** should be obtained every **1 to 2 years** in **asymptomatic patients** with **HCM** to monitor for **rhythm or conduction changes**.
16. **Ambulatory ECG monitoring** should be performed at diagnosis and repeated every **1 to 2 years** in **asymptomatic patients**, or sooner if **palpitations or syncope** occur.
17. **Transthoracic echocardiography (TTE)** should be repeated in **asymptomatic patients with HCM** every **1 to 2 years**, or sooner with **any change in clinical status or cardiac event**.
18. All patients with **known or suspected hypertrophic cardiomyopathy (HCM)** should undergo **three-generation family history assessment** and receive **genetic counseling**.
19. **Genetic testing** should be offered to patients who meet the **clinical definition of HCM**.
20. A **pathogenic variant** can be identified in up to **60% of patients** with **familial HCM** and in **20â€“30% of isolated cases**.
21. **First-degree relatives** of patients with **HCM** should undergo screening with **electrocardiography and echocardiography**.
22. In **first-degree relatives** who are **children or adolescents**, screening should occur **every 1 to 2 years**; in **adults**, screening should occur **every 3 to 5 years**, or sooner if **clinical status changes**.
23. **Genetic testing of first-degree relatives** is only informative if a **pathogenic variant has been identified in the index case**.
24. **Genotype-positive but phenotype-negative** individuals should undergo **clinical examinations** at standard screening intervals.
25. A **negative genetic test** in a patient with **HCM** does **not exclude familial disease**, and **first-degree relatives** should still be clinically screened.
26. **Genotype-negative relatives** in families with a known **pathogenic variant** do **not require ongoing clinical screening**.
27. Results of **genetic testing** in **HCM** are **not routinely used to guide treatment decisions**.

#### ðŸ’¬ Extra
1. Weight loss may reduce mechanical strain and risk of arrhythmia in HCM.
2. These factors reduce preload and can trigger dynamic obstruction in HCM.
3. Exercise supports cardiovascular health without triggering symptoms in most patients.
4. These agents reduce heart rate and contractility without promoting vasodilation.
5. Vasodilation can worsen dynamic obstruction by decreasing preload.
6. Disopyramide has been shown to improve symptoms when used with Î²-blockers in obstructive HCM.
7. Positive inotropes like digoxin exacerbate the gradient across the obstructed outflow tract.
8. HCM is independently associated with increased stroke risk.
9. DOACs are preferred due to ease of use and fewer interactions compared to warfarin.
10. Longer ambulatory monitoring may increase arrhythmia detection.
11. TTE surveillance evaluates changes in hypertrophy, obstruction, and valvular function.
12. Mavacamten requires enrollment in a REMS program due to risks of systolic dysfunction and mandates serial echocardiography.
13. Alcohol septal ablation may be preferred in high-risk surgical patients but has higher recurrence rates.
14. LVEF <50% in HCM is associated with increased mortality risk and justifies ICD placement.
15. Serial ECG helps identify silent conversion to atrial fibrillation or conduction abnormalities.
16. Increased frequency or severity of symptoms prompts early reassessment.
17. TTE is a key tool for monitoring progression of hypertrophy or new mitral regurgitation.
18. Family history may identify unrecognized HCM in relatives.
19. Clinical diagnosis is typically based on unexplained LV hypertrophy on imaging.
20. Higher detection rates are seen in familial cases compared to sporadic ones.
21. ECG/TTE together capture both electrical and structural disease markers.
22. Screening intervals are shorter in younger individuals due to growth-related expression.
23. Without a known variant in the proband, testing relatives may be inconclusive.
24. Phenotypic expression may occur later even in genotype-positive individuals.
25. Phenotype-based screening remains essential regardless of genetic test results.
26. This reduces unnecessary surveillance in genetically negative family members.
27. Treatment is guided by clinical phenotype, not genetic profile.

#### ðŸ”· Tags
#HypertrophicCardiomyopathy #LVOTObstruction #LifestyleModification #Metoprolol #Disopyramide #Digoxin #AmbulatoryMonitoring #TTE #Anticoagulation #DOAC #Warfarin #Mavacamten #ICD #SeptalMyectomy #AlcoholSeptalAblation #Surveillance #GeneticCounseling #GeneticTesting #FamilyScreening
